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1. Introduction 
Diabetes remains a fascinating condition to observe and treat, at least for the authors. The 
rewards of observing patients who remain free of complications many, many years after 
diagnosis is however negated by seeing the terrible consequences of diabetic complications 
which occur, not only in patients who have had the disease for many years but also in those 
who are found to have the disease when they first present with complications. The evolution 
of diabetes care has been fueled by new pharmaceutical agents and the large trials that have 
followed demonstrating benefit. There have of course been occasional trials that have upset 
patients, diabetologists and people looking after diabetes as well as the pharmaceutical 
industry. An example early in my career as a diabetologist was the University Group 
diabetes program (UGDP) [1] which suggested harm rather than benefit from the 
sulphonylurea Tolbutamide and the biguanide Phenformin. The controversy which this trial 
caused was truly amazing involving the Supreme Court in the United States. Not many 
trials have been scrutinized by a national supreme court. A more recent example is the 
ACCORD study [2] which set out to examine the benefit of reducing blood sugar to below 
6mmol/l. This study was stopped early because, although there was a reduction in 
myocardial infarction there was an increase in mortality. These trials have resulted in a 
magnificent increase in speculative literature and new consensus statements from lots of 
different bodies enthusiastic about giving advice through guidelines. The Annals of Internal 
Medicine is to be congratulated on publishing a paper written by Davidof “Music lessons; 
what Musicians can teach Doctors”[3]. The care of diabetes is certainly both an art and a 
science in 2011 and this article should re-enforce the diabetologist to be secure in practicing 
art as well as science in the management of diabetes. 
Cardiovascular disease is unfortunately the major cause of death in patients with diabetes. 
For example in the San Antonia Heart Study Halfner et al [4] demonstrated the increased 
risk of cardiovascular mortality in patients with diabetes but without a previous MI was the 
same as that of non diabetic patients who already have had MI although another study 
disputed this [5]. A third prospective study in Finland demonstrated similar results to the 
San Antonia Study [6] and a metanalysis in 2009 confirmed this relationship [7]. Looking at 
the situation in a different way it has been shown that diabetic patients have a life 
expectancy 8-15 years less than non-diabetic people. Recently a prospective study of men 
aged 60 – 69 years followed up for 9 years was reported [8]. The authors found that only 
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men with early onset diabetes and a duration of 16.7 years showed cardiovascular risk 
similar to those with MI and no diabetes. Late onset diabetes was also associated with 
increase in coronary artery events and all cause mortality compared to non diabetic men 
who had no coronary heart disease (CHD), but the risk was less. Even more worryingly is 
the evidence that as blood sugar rises but is still within the pre-diabetes range the risk of 
cardiovascular disease increases [9-11]. Indeed the risk increase in percentage terms is 
greater in this group of patients than in those with diabetes.  
Insulin resistance is a very early finding in the progression to diabetes and it has been 
suggested that abnormalities in fatty acid oxidation can be seen in close relatives of diabetic 
patients at an early age in adulthood [12,13] . A recent report from the Framingham Heart 
study has examined the effect of insulin resistance in subjects without diabetes. During a 
follow-up mean of 14 years the incidence of CHD was significantly greater in those with 
insulin resistance confirming previous studies that demonstrated that high insulin levels 
without hyperglycaemia was an important risk factor[14]. Hba1c has been shown to predict 
cardiovascular events and cardiovascular mortality independently of known cardiovascular 
disease [15-16]. These studies show a consistent and continuous relationship between 
glycaemia and cardiovascular risk even below diagnostic levels for diabetes. Chanman et al 
[17] have recently looked at non diabetic hyperglycaemia and cardiovascular risk and have 
demonstrated that in people with non-diabetic hyperglycaemia cardiovascular risk is highly 
dependent on the presence of other cardiovascular risk factors such as dyslipidaemia. These 
results are in keeping with the difficulty in demonstrating that lowering blood sugar 
improves cardiovascular outcome. There are of course some studies that show this ie 
Diabetes Control and complications/ Epidemiology of Diabetes Interventions and 
Complications (DCCT/EDIC) and UK Prospective Diabetes Study (UKPDS) follow-up 
[18.19]. However the original UKPDS did not show a significant effect on cardiovascular 
mortality [20]. A recent report from the FRENA registry [21] has shown in secondary 
prevention that patients with diabetes and HbA1c < 7% had a lower incidence of subsequent 
ischaemia and a lower mortality than those with HbA1c > 7%. These differences appeared 
only in patients with coronary artery disease (CAD). In this study more than 900 patients 
with type 2 diabetes were followed up over a mean period of 14 months [2, 21]. In the 
intensive care unit setting there was great excitement when studies showed that there was 
benefit from meticulous control of blood sugar but many studies since then have not 
confirmed these findings with regards to cardiovascular mortality [22,23].  
2. Atherosclerosis in diabetes  
Diabetes has been defined as an absolute or relative lack of insulin and it is therefore 
reasonable to consider the action of insulin and to recognize that deficiency in insulin does 
not lead only to hyperglycaemia but also to disturbance in fat and protein metabolism. 
Atherosclerosis is a condition of cholesterol and fat deposition in a vulnerable endothelium 
surface of an artery. It is not surprising therefore that attention has shifted, admittedly very 
slowly from the concept of dysglycaemia to dyslipidaemia for the cause of atherosclerosis in 
diabetes. Inspiration has come from the work of Shafrir and Guttman [24] who in 1965 
demonstrated the relationship between free fatty acids and blood sugar. They divided into 
quartiles, people ranging from normal blood sugar to impaired glucose tolerance. They 
demonstrated that non-suppression of free fatty acids occurred as the blood sugars rose 
even in the normoglycaemic range. In a thought provoking review many years later Shafrir 
and Raz [25] made the suggestion and gave strong evidence to support the suggestion that 
Diabetes Mellitus should be renamed “Diabetes Lipidus”.  
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Fig. 1. LDL may become modified by oxidation, and glycation. The macrophage takes up 
modified LDL and enters the subendothelial space where it becomes a cholesterol laden 
foam cell. Macrophage uptake is facilitated by cytokines and chemotactic factors such as 
VCAM and ICAM. Uptake of cholesterol from triglyceride-rich lipoproteins is facilitated by 
lipoprotein lipase on the endothelial cell surface. Smooth muscle cells protect the plaque 
from rupture through metalloprotinases and thrombus formation.  
Poorly controlled diabetes is usually associated with hypertriglyceridaemia which very 
often responds to hypoglycaemic therapy and normalization of blood sugars. The non-
suppression of free fatty acids (FFA) results in excess free fatty acids reaching the liver from 
adipose tissue which in turn leads to an increase in very low density lipoprotein (VLDL) 
secretion in the postprandial phase. The cellular concentration of non esterified fatty acids 
(NEFA) is tightly controlled by the balance between triglyceride hydrolysis and NEFA 
esterification [26-28]. The hydrolysis of the primary and secondary ester bonds between long 
chain fatty acids and the glycerol backbone in triglyceride is called lypolysis and depends 
on specific hydrolases commonly designated lipases. Adipose triglyceride lipase (ATGL) 
selectively performs the first and rate limiting triacylglyceride hydrolysis to form 
diacylglycerol and NEFA [29, 30]. Hormone sensitive lipase hydrolyses tri-, di- and 
monoacylglycerol [31]. Monoglyceride lipase efficiently cleaves monoglycerols into glycerol 
and NEFAs. Thus lipoprotein lipase, together with adipose triglyceride lipase, hormone 
sensitive lipase and hepatic lipase are all involved in the storage and release of FFA and are 
all involved in the metabolism of the triglyceride-rich lipoproteins and the suppression of 
fatty acids within the adipocyte. Insulin has a direct effect in inhibition of hormone sensitive 
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lipase and ATGL which releases fatty acids from the adipocyte and stimulates lipoprotein 
lipase which is involved in the delipidation of the triglyceride-rich lipoproteins necessary 
for lipoprotein clearance and FFA storage in the adipocyte. For review see Lass et al 2011 
[32]. NEFA metabolism strongly effects glucose utilization and insulin resistance. ATGL 
affects glucose metabolism by different mechanisms and in a tissue specific manor ie 
measures of insulin signaling are increased in skeletal muscle and white adipose tissue but 
decreased in brown adipose tissue [33]. In pancreatic islets ATGL deficiency causes 
triglyceride accumulation and impairs fuel and non fuel stimulated insulin secretion 
suggesting that ATGL is required for the provision of NEFAs as energy source in the 
process of insulin secretion. 
 
 
Fig. 2. LDL is cleared from the plasma by uptake by the apo B/E receptor in coated pits on 
the cell surface. The receptor is internalised and transported to the endosome where LDL is 
degraded and the cholesterol released. The receptor is normally recycled to the cell surface. 
PCSK9 is secreted into the pasma and binds to the LDL receptor inhibiting recycling of the 
receptor. Statins work by upregulating the LDL receptor and facilitating LDL clearance but 
they also upregulate PCSK9. 
Cholesterol as a risk factor for atherosclerosis is so well documented that further 
confirmation seems unnecessary. The safety and efficacy of lowering cholesterol is also well 
established [34]. Long term prospective studies such as Framingham laid the foundations 
but examination of monogenetic hypercholesterolaemia, whether it be from apo B 
polymorphisms, the low density lipoprotein (LDL) receptor or the recent pro-protein 
convertase subtilism-like/kexin type 9 (PCSK 9) already had made the association between 
hypercholesterolaemia and atherosclerosis. PCSK9 is of particular interest since there are 
both loss of function and gain of function gene polymorphisms. In 2003 Abifidel et al [35] 
reported 23 families with autosomal dominant hypercholesterolaemia and premature CHD 
caused by missense mutations of PCSK9. Haughton et al in 2007 [36] demonstrated that over 
expression of PCSK9 in livers of mice reduced hepatic LDL receptor protein causing 
hyperchlesterolaemia suggesting that the mis sense mutations caused a gain of function to 
the mutant protein. They also showed that inactivation of PCSK9 resulted in 
hypocholesterolaemia. Loss of function mutations have also been identified in patients with 
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hypocholesterolaemia. What is particularly interesting is that the reduction in cholesterol 
with these loss of function mutations is associated with much less coronary artery disease 
than would be expected with a similar reduction in cholesterol using statins. An explanation 
has been that the miss-sense mutation has been there since birth whereas statins are only 
used in middle age [37]. Statin therapy in heterozygous patients with this polymorphism 
has a much greater effect than would be associated with statins alone and these findings 
have been used to promote the idea that early statin use would increase benefit [37]. Statins 
upregulate sterol regulatory element binding protein (SREBP) which upregulates the LDL 
receptor but also causes a 45% increase in PCSK9 and a 70% increase when ezetimibe is 
added to the statin [38]. This is probably through regulation by SREBP thus development of 
cholesterol lowering drugs which do not increase PCSK9 would be very advantageous [39]. 
PCSK9 promotes LDL uptake by the LDL receptor but reduces the number of LDL 
receptors. Exciting animal studies suggest that inhibitors of PCSK9 may prove to be a 
powerful tool in cholesterol lowering particularly in conjunction with statins [40]. The 
Sammomys obesus (sand rat) has been very successfully used as a nutritionally-induced 
type 2 diabetes model [41]. Levy et al [42] investigated intestinal PCSK9 protein in this 
model and found that the protein was diminished and LDL receptor was raised in the 
diabetic compared to non-diabetic Sammomys. To investigate whether PCSK9 expression in 
diabetic patients played a part in diabetic dyslipidaemia, Brouwers et al [43] in the CODAM 
study measured PCSK9 in subjects with normal glucose metabolism with impaired glucose 
metabolism and type 2 diabetes. They found no difference in plasma PCSK9 between the 3 
groups. Their study did suggest that the presence of type 2 diabetes may modify the 
relationship between plasma PCSK9 non-HDL cholesterol and apo B.  
Early studies with statins such as the 4S study, demonstrated that diabetic patients responded 
better if anything than non-diabetic patients to statin therapy [44]. Other studies such as the 
Heart Protection Study [45.46] suggested that the response was similar in diabetic and non-
diabetic patients. The role of hypertriglyceridaemia as a risk factor is less secure, perhaps 
because of the very strong inverse relationship between HDL cholesterol and the strong 
evidence that HDL protects against MI through various pathway [47]. Four years ago 2 
important large studies demonstrated convincing evidence of the association between 
hypertriglyceridaemia and cardiovascular disease [48, 49]. Both these studies suggested that 
postprandial triglycerides are effective in predicting cardiovascular risk which fits in well with 
the concept of the atherogenicity of postprandial lipoproteins as will be discussed later. A 
recent examination of the diabetic patients in the Dutch and Potsdam contributions to the 
European Investigation into Cancer and Nutrition[50,51] was reported. The aims of the study 
were to examine the effects of postprandial time on the association and predictive value of 
non-fasting lipid levels and cardiovascular disease risk in participants with cardiovascular 
disease and diabetes. More than 1300 participants with diabetes at baseline were analysed. A 
cut off time between the groups of 3 hours was used in the assessment of cardiovascular risk 
prediction. The authors concluded that postprandial time did not influence the association of 
lipid concentrations with CVD in patients with diabetes nor did it effect a prediction of CVD 
risk [52]. The dramatic effects of cholesterol reduction with statins in reducing cardiovascular 
events has not been replicated using drugs such as fibrates which lower triglycerides although 
studies such as the DIAS study [53] did show significant lack of progression of coronary artery 
atherosclerosis using fenofibrate and the FIELD study [54] did show a significant reduction in 
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the composit of CVD death, MI, stroke and coronary or carotid revascularization, even though 
many patients in that study had statins added to the treatment during that study and only 21% 
of patients enrolled had mixed dyslipidaemia, thus limiting its power. Also the Field Study 
[54] chose patients who did not have very elevated triglyceride levels which was anther 
problem with the study. A recent metanalysis systematically searched trials published 
between 1950 and 2010 and found that fibrates produced a 10% relative risk reduction for 
major cardiovascular events and a 13% relative risk reduction for coronary events (p<0.001) 
but had no effect on all risk or cardiovascular mortality[55]. Supporting the concept that 
fibrates may show more benefit in patients with hypertriglyceridaemia, Scott et al [56] on 
behalf of the Field Study Investigators explored whether the effect of fenofibrate on 
cardiovascular risk differed in subjects with and without metabolic syndrome. There were 
more than 9000 individuals with diabetes and components of the metabolic syndrome. They 
observed that the largest effect of fenofibrate on CVD risk was in patients with marked 
hypertriglyceridaemia (triglyceride >2.3) in whom a 27% risk reduction was observed with or 
without a low HDL cholesterol. From the above it becomes clear that diabetes is associated 
with an increased risk of atherosclerosis which can in part be reduced by either lowering LDL 
cholesterol or triglycerides. 
3. The chylomicron in diabetes 
The food we eat ( quantity and quality) is responsible for the variation in an individuals 
lipoprotein profile accepting that the variation may be modified by exercise. This regulation 
is considerably disturbed in diabetes. It is important to recognize the role of the triglyceride-
rich lipoproteins and in particular the chylomicron in modulating both VLDL and LDL 
quantity and composition [57]. High density lipoprotein (HDL) is also intimately linked to 
the triglyceride rich lipoproteins with a strong inverse correlation. Thus the chylomicron 
assumes dominance over all other lipoproteins particularly in diabetes and makes the study 
of chylomicron metabolism exciting and of major importance in the pathophysiology of 
diabetes, dyslipidaemia and atherosclerosis.  
The chylomicron is defined by apolipoprotein (apo) B48 its solubilising protein. Many 
studies have shown an increase in the apo B48-containing lipoproteins both in the 
postprandial and fasting state in diabetes [58]. Originally it was thought that the problem 
was in clearance of the particles due to a relative lack of insulin which led to a reduction in 
lipoprotein lipase activity, slowing of lipolysis of the particle and delayed clearance by the 
liver. We demonstrated in an animal model of diabetes that chylomicron synthesis was also 
abnormal and confirmed that because of altered composition of the particle clearance was 
delayed perhaps due to insufficient apo E on the particle [59]. The regulation of chylomicron 
synthesis in the intestine is dependent on the amount of cholesterol that is available in the 
diet but chylomicron cholesterol also comes from the enterohepatic secretion of bile and the 
cholesterol that is excreted from the liver via this route as well as de novo cholesterol 
synthesis. The intestine is responsible for up to 25% of the cholesterol synthesized in the 
body. As an interesting aside at this stage it is useful to consider that people have been 
categorised into high and low absorbers of cholesterol and that cholesterol absorption is 
inversely related to cholesterol synthesis. As expected the high absorbers do less well on 
statin therapy but better on inhibition of cholesterol absorption by Ezetimibe, a drug that 
inhibits cholesterol absorption, compared to the people who are low absorbers of 
cholesterol. In the Framingham offspring study those patients with lower synthesis and 
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higher absorption markers were more likely to develop cardiovascular disease [60,61]. These 
studies were confirmed by Silbernagel et al [62]. In 2440 participants of the LURIC study 
they found a modest association of high cholesterol absorption and low cholesterol 
synthesis with an increased severity of CAD. However Lakoskiet al [63] tested the 
hypothesis that individuals with high fractional absorption of cholesterol respond better to 
the cholesterol absorption inhibitor Ezetimibe than to simvastatin and visa versa. They did 
not find that baseline cholesterol absorption and synthesis predicted responsiveness to the 
above drugs rather they found that responsiveness to the two drugs was highly correlated. 
They suggest that factors downstream of the primary sites of action of these drugs are a 
major determinant of the response. In a subgroup analysis of the Scandinavian  Simvastatin 
Survival Study (4S), Miettinen et al [64] showed that the baseline blood glucose level is 
related positively to cholesterol synthesis and negatively to that of absorption. Despite a 
marked glucose-related decrease in cholesterol synthesis with simvastatin, serum 
cholesterol reduction was not dependent on the baseline glucose level. 
The discovery of Niemann Pick C1-like1(NPC1-L1) is an interesting story. The search for an 
explanation as to how cholesterol in the body is so finely regulated has been intensive. The 
finely tuned regulation of cholesterol was perhaps best illustrated by the report of the elderly 
gentleman who ate 25 eggs a day for many years but his cholesterol remained at just above 
6mmol/l [65]. Altman and Davis in their search for molecules that might inhibit cholesterol 
absorption discovered by chance a compound which is now known as ezetimibe [66]. They 
discovered a putative gene, the NPC1L1. Elegant studies in mice demonstrated that knocking 
out this gene reduced cholesterol absorption by the same amount as happened when the wild 
mice were fed with ezetimibe. They showed that there was no further reduction in cholesterol 
absorption in the knockout mice when fed ezetimibe. The group went on to show that lack of 
Npc1L1 in apoE–/– mice results in a significant reduction in cholesterol absorption and plasma 
cholesterol levels, and causes nearly complete protection from the development of 
atherosclerosis, under both cholesterol-fed and non-cholesterol-fed conditions [67, 68]. Statins, 
which inhibit 3 Hydroxy 3 methylglutaryl co enzyme A (HMGCoA) reductase and cholesterol 
synthesis, have been shown to increase cholesterol absorption. It has also been shown that low 
absorbers of cholesterol respond better to statins than high absorbers. Ezetimibe potentiates 
the effect of statins, increasing their effectiveness by another 15 – 20% in relation to cholesterol 
lowering. Trembly et al [69] this year reported an increase in NPC1L1 by 19% in the small 
intestine in subjects on atorvastatin thus describing a mechanism whereby cholesterol 
absorption is increased in patients on statins. In animal studies we have demonstrated an 
increase in cholesterol absorption in diabetes [70] We asked the question as to whether 
diabetes might be associated with an increase in cholesterol absorption through stimulation of 
NPC1-L1. We demonstrated in animal models of diabetes that NPC1L1 was up-regulated [71] 
and in diabetic patients and we demonstrated an increase in mRNA [72] suggesting a 
mechanism for an increase in cholesterol absorption. In the Sammomas Obesus model of type 
2 diabetes, the animals exhibiting weight gain, hyperinsulinaemia and hypercholesterolaemia, 
NPC1-L1 protein and gene expression were both significantly reduced in the intestine and the 
authors found a lower capacity to absorb cholesterol compared to controls [73,]. This may 
suggest interspecies variation but it is a surprising finding considering that this animal model 
of diabetes has been shown to have increased production of intestinal lipoprotein-containing 
apo B48 [74].  
The mechanism whereby the body is almost completely unable to absorb plant sterols was a 
mystery until recently. Study of the familial condition, sitosterolaemia, unlocked the 
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mystery [75]. Sitosterolaemia is a rare condition associated with early and severe 
atherosclerosis. The condition is associated with normal or slightly elevated cholesterol 
whereas total sterols are markedly increased. Search for polymorphisms in putative genes 
controlling plant sterol absorption or perhaps one should say blocking plant sterol 
absorption, identified ATP binding cassette proteins (ABC)G5 and G8 in the intestine [76]. 
Further work demonstrated that these two gene products work in tandem to re-excrete both 
plant sterols virtually completely and cholesterol to a lesser extent in a regulated way [77]. 
The genes were also found to be expressed in the liver where they are responsible for 
controlling cholesterol re-excretion into the bile [75-77]. It appears that these two genes are 
very important regulators of cholesterol and together with NPC1-L1 protein are responsible 
for cholesterol homeostasasis in the body. Polymorphisms of the ABCG5/G8 have not only 
been associated with increased serum sitosterol but also with increase in cholesterol. It has 
also been shown that polymorphisms in the ABCG5/G8 may influence cholesterol in weight 
reduction programs (the Q604E SNP in ABCG5 and the C54Y in ABC8) [78,79]. Gylling et al 
[80] examined polymorphisms in the ABCG5 and G8 genes and found that low serum 
cholesterol and cholesterol absorption were linked to a polymorphism (D19H) of the ABCG8 
gene and characteristics of the insulin resistance syndrome in men was linked to Q604E 
polymorphism in the ABCG5 gene. The authors studied 263 mildly hypercholesterolaemic 
non-coronary subjects using colestanol to cholesterol ratio as a surrogate marker of 
cholesterol absorption efficiency. Since diabetes is so frequently associated with 
dyslipidaemia the ABCs became a target for research. Blocks et al [81] examined mRNA and 
protein expression of ABCG5 and G8 in the intestine of streptozotosin rats and found 
significant reduction in expression of both ABCG5 and G8. They found that levels were 
partially normalised on insulin supplementation. We have shown that ABCG5 and G8 were 
reduced by more than 50% in the intestine of zucker diabetic fa/fa rats compared with lean 
rats although this did not reach statistical significance [82]. Insulin treatment caused a non-
significant increase in ABCG5 and G8 mRNA. In streptozotosin diabetic rats ABCG5 and G8 
were both very significantly reduced in the intestine [83]. There was a negative correlation 
between both ABCG5 and G8 and chylomicron cholesterol [83]. In the Psamonas Obesus 
Levy et al [73,74] showed a reduction in ABC G5/G8 in the intestine. In the intestine of 
human subjects with type 2 diabetes, ABCG5 and G8 mRNA were both significantly lower 
compared to controls [71]. There was a negative correlation between ABCG5 and G8 and 
NCP1-L1 in the combined diabetic and control subjects [71]. There was a significant negative 
correlation between chylomicron cholesterol and both ABCG5 and G8 [71]. These two genes 
appear to play an important role in the dysregulation of cholesterol metabolism in diabetes 
4. Microsomal triglyceride transfer protein  
Intestinal microsomal triglyceride transfer protein (MTP) plays a major role in the assembly 
of the chylomicron particle and therefore of cholesterol and triglyceride metabolism. 
Intestinal MTP has become a hot topic since new inhibitors of intestinal MTP have been 
shown to lower triglyceride without causing hepatic steatosis at least in animal studies 
[84,85]. Although many polymorphisms of MTP have been described, some of which have 
considerable impact on LDL cholesterol in both non-diabetic and diabetic subjects [86,87], it 
is difficult to know whether the results mainly stemmed from the effect in the liver rather 
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than the intestine. The intestinal inhibitors of MTP which have no effect on the liver, should 
answer this question in the future. In animal studies diabetes is associated with an increase 
in MTP mRNA with close correlation between MTP mRNA and chylomicron 
cholesterol[81,88-90]. In the rabbit increased MTP mRNA is associated with increase in 
chylomicron particle numbers [88] but in the rat it is associated with larger particles [89]. 
The fructose-fed insulin resistant hamster model, has an increase in MTP protein mass and 
this was associated with an increase in the triglyceride-rich intestinally derived lipoproteins 
[91]. Zolotowska et al [92] in 2003 examined the B48 containing lipoprotein assembly in the 
small intestine of psamnonys obesus, a model of nutritionally-induced diabetes and insulin 
resistance. De novo triglyceride synthesis, apo B48 biogenesis and triglyceride-rich 
lipoprotein assembly were all increased. MTP activity and protein expression however, 
were not altered. In the enterocyte of fructose fed golden hamster MTP mRNA and protein 
mass were increased by tumour necrosis factor(TNF)α but apo B levels in the enterocyte 
were not effected suggesting that there is considerable inter species variation [91]. In human 
studies in type 2 diabetes we demonstrated an increase in MTP mRNA in intestinal biopsies 
[71,90]. Diabetic patients who were on statin therapy had lower MTP mRNA compared to 
those not on statins [86,]. We found positive correlations between MTP mRNA and 
chylomicron fraction cholesterol and apo B48 [86]  
5. Chylomicron and atherosclerosis 
The circulating chylomicron has been the poor relation of the lipoproteins, at least until 
recently. There are many reasons for this ie post postprandial lipoprotein measurement is 
difficult to standardise. The amount of cholesterol that the chylomicron contains is very 
much less than that of the LDL particle and the statins have demonstrated such resounding 
success in reducing cholesterol and lowering cardiovascular risk. Those of us who champion 
the chylomicron as the most important lipoprotein do so in part because the number of 
chylomicrons, far exceeds that of LDL particles. Chylomicrons in fact carry as much 
cholesterol as LDL particularly in high cholesterol absorbers. They have a turnover in 
minutes whereas LDL has a half life of about 4 days. The lipoproteins are a transport 
mechanism for cholesterol and fat thus the shorter the half life the more the carrying power. 
The atherogenicity of the chylomicron particle depends on its ability to deliver cholesterol to 
the atherosclerotic plaque and studies both in animals and humans have demonstrated that 
indeed apo B48 is found in plaque demonstrating that the chylomicron can enter the 
endothelial space. The macrophage has a specific apo E receptor which enhances the uptake 
of the chylomicron particle. The composition of the chylomicron particle in diabetes has 
been difficult to define because separation of apo B48 particles from apo B100 particles is 
cumbersome. Using a monoclonal antibody against apo B48, Yoshimura et al [92] examined 
type 2 diabetic patients and non-diabetic patients. Although the separation of apo B48 from 
B100 was not complete the apo B48 containing chylomicrons had a higher content of 
triglyceride but there was no difference between those with diabetes and those without 
diabetes. They further confirmed a B48 receptor in TPH-1 cells (a human acute monocytic 
leukaemia cell line) and also in Hep G2 cells. The inflammatory process is at the centre of 
the atherosclerotic lesion. Chylomicron remnants induce macrophage foam cell formation 
[93,94]. The fatty acid composition of chylomicron remnants markedly influences the 
formation of macrophage foam cells. The group from the Royal Veterinary College in 
London has shown that enrichment with saturated fatty acids causes the remnants to be  
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Fig. 3. The chylomicron is formed from dietary cholesterol, triglyceride, and phospholipid 
together with endogenously synthesised cholesterol for which HMGCoA reductase is the 
rate-limiting enzyme, and Some of the cholesterol is esterified by the enzyme ACAT. 
Intestinal cholesterol absorption is facilitated by NPC1L1 and opposed by ABCG5/G8. 
Intestinally produced apo B48 is the structural protein for the chylomicron and the particle 
is assembled under the influence of MTP. Most of the chylomicron triglyceride is hydrolised 
by lipoprotein lipase in the capiliaries prior to uptake of the particle by the liver where it is 
broken down and reassembled together with apo B100, again under the influence of MTP, 
and released as VLDL into the circulation. 
taken up more quickly and cause greater cholesterol accumulation than those enriched with 
polyunsaturated fatty acids or monounsaturated fatty acids [95]. They further showed that 
the inflammatory process and the activity of nuclear factor-kB (NF-kB can be diminished if 
the Chylomicron remnants are enriched with polyunsaturated fatty acids [96]. This group 
had previously shown that oxidation of chylomicron remnants delayed uptake by the 
macrophage CD36 receptor in contrast to LDL where oxidation increases uptake in 
macrophages. The authors however do make the point that the CD36 receptor and 
phagocytosis play only a minor role in foam cell formation. The main uptake and 
internalisation being through the LDL receptor related protein (LRP) and the LDL receptor 
[97]. GLP-1-like agonists are now being widely used in the treatment of diabetes and have a 
beneficial effect on glycaemia and also lipidaemia [98]. Xiao et al 2011 [99] have recently 
shown in healthy men that glucagon acutely regulates hepatic but not intestinal lipoprotein 
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metabolism both by decreasing lipoprotein particle production and inhibiting particle 
clearance. The classic diabetes fasting lipid indices of elevated LDL cholesterol, high 
triglyceride and low HDL in those with type 1 diabetes is often missing even if they have 
atherosclerosis[100]. However when adolescents with diabetes are compared to their non-
diabetic siblings they have been shown to have higher triglycerides. LDL and lower HDL 
[101]. The SEARCH for diabetes in youth study (SEARCH) showed similar findings [102]. 
Guy [103] in a cross sectional study of 512 youths with type 1 diabetes mean duration 4.2 
years and 188 healthy control subjects they found that those with HbA1c in the optimal 
range (<7.5%) were similar to controls whereas the poorly controlled subjects had raised 
total cholesterol, LDL cholesterol and non-HDL cholesterol together with significantly 
elevated apo B and more small dense LDL particles. The authors conclude that poor 
glycaemic control is an important mediator of abnormal lipoproteins. Very recently Mangat 
et al [104] examined the chylomicron in subjects with type 1 diabetes thus extending our 
knowledge of postprandial lipoprotein metabolism in diabetes. Just like in type 2 diabetes 
[105-107], Mangat et al show significantly higher concentrations both of fasting apo B48 and 
a total plasma apo B48 following a sequential meal challenge, than control subjects 
demonstrating impaired metabolism of chylomicron remnants. Interestingly they also 
demonstrated arterial retention of remnants ex vivo in type 1 diabetic rats and showed that 
remnants bound with significant affinity to human biglycan in vivo. They also showed a 
further 2.3 fold increased binding capacity when they used glycated biglycan.  
6. Chylomicron turnover in diabetes 
The chylomicron is mostly cleared by the liver through the B/E and LDL related protein 
(LRP) receptors. There is prolonged clearance in diabetes as shown by the length of time apo 
B48 remains in the circulation following a meal [105-107]. This is related both to 
compositional abnormalities in the chylomicron and to delay in lipolysis. As stated earlier 
apo E appears to be deficient on the particle [59]. Perhaps more importantly delipidation of 
the particle is abnormal. Lipoprotein lipase is an insulin dependent enzyme and in clinical 
practice treatment that normalises blood sugar is always associated with a reduction in 
triglyceride. The importance of the postprandial period in triglyceride metabolism and 
particularly in chylomicron metabolism is often overlooked with reliance on fasting blood 
sugar as being an indication of good diabetic control. The evidence that the postprandial 
blood sugar is a better indicator of cardiovascular risk than fasting blood sugar and the close 
relationship between hyperglycaemia and hypertriglyceridaemia suggests that 
normalisation of both blood sugar and triglycerides would reduce the atherosclerotic 
burden Cereillo [108]. Interest is growing in measurement and treatment of the postprandial 
phase but it is very demanding on both patient and physician. The increase in 
chylomicronaemia postprandially has a major impact on VLDL composition since the large 
triglyceride-rich lipoproteins generate small dense LDL [109 110]. Small dense LDL has been 
shown to be more easily oxidised and therefore has a greater capacity to be taken up by the 
macrophage. Small dense LDL is more common in diabetes. Many years ago the Scottish 
group were unable to show much in the way of a relationship between small dense LDL and 
atherosclerosis in diabetes [111] but more recently in a small study it has been reported LDL 
size was the stongest marker for clinically apparent as well as non apparent atherosclerosis 
In Type 2 diabetes [112]. Inhibition of cholesterol absorption with Ezetimibe improves the 
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quality of VLDL, IDL and LDL by significantly reducing the triglyceride/cholesterol ratio in 
these lipoproteins [113] demonstrating the relationship between the chylomicron and the 
other apo B containing lipoproteins. 
7. High density lipoprotein 
The intimate inverse relationship between triglyceride-rich lipoproteins and HDL is well 
known and is particularly common in diabetes. The reason why this inverse correlation is so 
strong is due to the importance of apo A1 and apo E in the formation of HDL. Catabolism of 
the triglyceride-rich lipoproteins is necessary for the release of apo A1 and apo E, both 
intestinally and hepatically derived. The delayed catabolism of the triglyceride-rich 
lipoproteins in diabetes leads to a deficiency of apo A1 and apo E necessary for the 
formation of the nacent HDL particle with its specific detergent-like properties that can 
solublise vesicular phospholipid to create discoidal HDL particles [114]. Lipoprotein 
metabolism starting with the large chylomicron and ending with the small HDL particles is 
a closely interwoven dynamic milieu designed in times when food was in short supply. It is 
not surprising that disturbance of this intricate pathway occurs with over feeding or in 
diabetes when a lack of insulin relative or absolute disturbs energy metabolism. 
8. Conclusion  
The chylomicron is a major cholesterol carrying particle due to the large amount of 
chylomicrons produced postprandially. Chylomicron cholesterol is delivered to the 
atherosclerotic plaque and induces foam cell formation. Chylomicron clearance is delayed in 
diabetes but synthesis is also increased in diabetes. The other important cause of 
atherosclerosis in diabetes relates to the lipoprotein cascade, increased chylomicron 
production and decreased clearance leads to an atherogenic LDL (both small dense LDL and 
an LDL with an increase in esterified cholesterol) leading to increased oxidisability of the 
particle. Finally the increase in triglyceride-rich lipoproteins results in low HDL, an 
important atherosclerosis risk factor. Normalisation of the dyslipidaemia of diabetes and in 
particular chylomicronaemia should be a major goal in the prevention of the increased 
atherosclerosis found in diabetes 
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